Sudden Cardiac Death in Dialysis Patients and the ICD

Sudden cardiac death is a major cause of mortality among people receiving maintenance dialysis. The mechanism is often more complex than a single sustained ventricular tachycardia: rapid shifts in potassium and calcium, myocardial fibrosis, left ventricular hypertrophy, autonomic imbalance, ischaemia, and bradyarrhythmia may converge during or shortly after a dialysis session. This makes prevention clinically important, yet it also makes device-based protection difficult to evaluate.

An implantable cardioverter-defibrillator (ICD) can terminate ventricular tachycardia or ventricular fibrillation, but its benefits must be weighed against infection, venous access problems, inappropriate shocks, procedural complications, and competing illness. For Australian clinicians, decisions are shaped by access to electrophysiology services, the organisation of renal care, rural and remote travel, and the patient’s goals for treatment. Current research and educational material in this field can be followed through the Journal of Arrhythmia, the official publication of major heart rhythm societies in the Asia-Pacific region.

Why Dialysis Amplifies Arrhythmic Risk

Patients with end-stage kidney disease commonly have structural and electrical substrates for malignant arrhythmia. Long-standing hypertension, diabetes, coronary artery disease, uraemic cardiomyopathy, and left ventricular dysfunction can produce scar and abnormal conduction. Fibrosis of the myocardium and conduction system may support both re-entry tachycardia and profound bradycardia.

The dialysis cycle adds a changing physiological load. Potassium concentration may fall quickly during treatment, while shifts in calcium, bicarbonate, and fluid volume influence repolarisation and myocardial excitability. The interval between treatments can also allow potassium and fluid to accumulate. These factors help explain why sudden deaths may cluster during dialysis or in the hours that follow, although many events occur without a documented shockable rhythm.

A careful history should include syncope, unexplained falls, palpitations, intradialytic hypotension, previous cardiac arrest, and family history of sudden death. Reviewing dialysis records can reveal recurrent electrolyte disturbances or episodes of rapid ultrafiltration that are not apparent in a routine cardiology consultation.

What an ICD Can and Cannot Prevent

The strongest rationale for an ICD is usually secondary prevention: survival from ventricular fibrillation or sustained ventricular tachycardia without a reversible cause. In such cases, an ICD may provide meaningful protection, provided the patient’s overall prognosis and preferences support implantation. Reversible triggers, including severe hyperkalaemia, acute ischaemia, drug toxicity, or dialysis-related instability, should be addressed before attributing the event to a persistent arrhythmic substrate.

Primary prevention is less straightforward. Standard ICD criteria based on reduced left ventricular ejection fraction were developed largely in populations that did not have the same burden of kidney failure. In dialysis cohorts, the absolute reduction in sudden death may be smaller because deaths may arise from pulseless electrical activity, asystole, stroke, infection, progressive heart failure, or other non-shockable causes.

An ICD does not correct the causes of electrical instability created by dialysis. Optimising the dialysis prescription, avoiding abrupt electrolyte changes, treating coronary disease and heart failure, reviewing QT-prolonging medicines, and managing sleep apnoea may be equally important. Device therapy should therefore sit within a broader sudden-death prevention plan rather than replace renal and cardiovascular risk management.

Evidence, Selection, and Shared Decisions

Observational studies have produced mixed results for prophylactic ICD implantation in dialysis patients. Some cohorts suggest benefit in carefully selected individuals, while others show little survival advantage after accounting for age, frailty, infection, diabetes, heart failure severity, and comorbidity. The absence of a clear universal benefit means that an automatic device strategy is difficult to justify.

Selection should consider expected survival with acceptable function, reversible causes, ventricular function, documented rhythm, transplant candidacy, and the likelihood that the patient can attend follow-up. A younger patient with a prior ventricular fibrillation arrest and a realistic path to kidney transplantation may have a different risk-benefit balance from an older person with severe frailty, recurrent sepsis, advanced peripheral vascular disease, and limited life expectancy.

Shared decision-making needs plain language. Patients should understand that an ICD can deliver a painful shock, may require lead revision or extraction, and can become a source of distress near the end of life. Discussions should cover deactivation in advanced illness, who will manage the device, and how dialysis, cardiology, electrophysiology, and palliative care teams will communicate.

Australian practice also requires attention to geography. A patient living in a remote community may need flights or long road journeys for implantation and interrogation, while someone in Sydney, Melbourne, Brisbane, Perth, Adelaide, or another major centre may have more immediate access to an electrophysiology service. These practical burdens belong in the clinical decision, not as an afterthought.

Implantation Challenges and Device Options

Vascular access is a central issue. Haemodialysis patients may have arteriovenous fistulas or grafts, central venous stenosis, previous catheters, and limited sites for future access. Transvenous ICD leads can complicate venous drainage, interact with an access circuit, and become difficult to remove if infection develops. The implanting team should map existing and planned access, coordinate with nephrology and vascular surgery, and avoid compromising a limb that may be needed for dialysis.

Infection carries particular significance. Repeated access to the bloodstream, diabetes, immune dysfunction, and frequent hospital exposure can increase the consequences of a device infection. A pocket infection or lead endocarditis may require complete system extraction, prolonged antimicrobial treatment, and temporary protection during a high-risk period. Perioperative planning should address antibiotic stewardship, anticoagulation, dialysis timing, and the safest route for vascular access.

A subcutaneous ICD can avoid intravascular leads and may be attractive when venous preservation is critical. It cannot provide conventional bradycardia pacing, antitachycardia pacing, or cardiac resynchronisation, so it is unsuitable for patients who need those functions. Leadless pacing is another specialised option when pacing is required and transvenous hardware is undesirable; a focused discussion of leadless pacing in valve disease illustrates how device selection depends on anatomy and the clinical problem rather than a single preferred technology.

Managing Shocks, Dialysis, and Follow-Up

After implantation, the renal and cardiac teams should agree on a surveillance plan. Device interrogation can identify ventricular arrhythmias, atrial fibrillation, lead problems, battery status, and delivered therapies. Remote monitoring may reduce travel, although reliable connectivity, digital confidence, and local clinical support cannot be assumed for every Australian patient.

An ICD shock requires prompt assessment, even when the patient feels well. The review should determine whether the event was appropriate, examine potassium, magnesium, calcium, acid-base status, and volume state, and review recent dialysis parameters and medicines. Recurrent shocks may indicate an urgent need for reprogramming, antiarrhythmic therapy, catheter ablation, coronary assessment, or a revised dialysis strategy.

The device should be incorporated into emergency planning at the dialysis unit. Staff need to recognise sustained ventricular arrhythmia, initiate cardiopulmonary resuscitation, use an external defibrillator when indicated, and understand that an ICD does not prevent cardiac arrest from every cause. Magnet use and shock management should follow local protocol and advice from the treating electrophysiology service.

Access to the Australian market also influences follow-up. Device availability, programming capability, specialist coverage, and reimbursement pathways can differ between public hospitals, private facilities, and regional services. Coordination with renal units across state health systems is especially important when a patient transfers between hospitals or travels for holidays.

A Practical Framework for Australian Care

Evaluation should begin with the event itself: was there a documented shockable rhythm, or is sudden death being inferred from an unwitnessed collapse? The next steps are to correct reversible triggers, assess ventricular function and coronary disease, review dialysis-related haemodynamic and electrolyte patterns, and estimate competing mortality. Frailty, cognitive status, transplant plans, and the patient’s priorities should be recorded alongside conventional cardiology measurements.

A multidisciplinary conference can be valuable when the decision is uncertain. Nephrologists, electrophysiologists, general cardiologists, dialysis nurses, vascular specialists, and palliative care clinicians may each identify risks that are missed in an isolated consultation. For Aboriginal and Torres Strait Islander patients and people from remote communities, culturally safe communication and practical support are essential; a technically appropriate device may still fail to deliver benefit if follow-up is inaccessible or care is poorly coordinated.

Prevention also extends beyond the device. Dialysis prescriptions should avoid unnecessary rapid electrolyte and volume shifts, medication lists should be reconciled regularly, and symptoms suggesting coronary disease or heart failure should receive timely attention. Where an ICD is chosen, the indication, expected benefit, complications, follow-up arrangements, and future deactivation plan should be documented clearly.

A considered approach recognises that the relevant question is not simply whether a patient meets a device threshold. It is whether an ICD is likely to improve meaningful survival for that individual, given the mechanism of risk, the feasibility of implantation, the burden of dialysis, and the patient’s values.

For clinicians and trainees, ongoing review of electrophysiology evidence is essential as device technology, dialysis practice, and risk-stratification methods develop. Explore current research, clinical reviews, and educational resources through the Journal of Arrhythmia, and apply a multidisciplinary, patient-centred framework when assessing ICD therapy for people receiving dialysis.